Article Versions Notes

Kocsmár I, Kocsmár É, Pajor G, Kulka J, Székely E, Kristiansen G, Schilling O, Nyirády P, Kiss A, Schaff Z, et al. Addition of Chromosome 17 Polysomy and HER2 Amplification Status Improves the Accuracy of Clinicopathological Factor-Based Progression Risk Stratification and Tumor Grading of Non-Muscle-Invasive Bladder Cancer. Cancers. 2022; 14(19):4570. https://doi.org/10.3390/cancers14194570

Kocsmár, Ildikó, Éva Kocsmár, Gábor Pajor, Janina Kulka, Eszter Székely, Glen Kristiansen, Oliver Schilling, Péter Nyirády, András Kiss, Zsuzsa Schaff, and et al. 2022. "Addition of Chromosome 17 Polysomy and HER2 Amplification Status Improves the Accuracy of Clinicopathological Factor-Based Progression Risk Stratification and Tumor Grading of Non-Muscle-Invasive Bladder Cancer" Cancers 14, no. 19: 4570. https://doi.org/10.3390/cancers14194570

Kocsmár, I., Kocsmár, É., Pajor, G., Kulka, J., Székely, E., Kristiansen, G., Schilling, O., Nyirády, P., Kiss, A., Schaff, Z., Riesz, P., & Lotz, G. (2022). Addition of Chromosome 17 Polysomy and HER2 Amplification Status Improves the Accuracy of Clinicopathological Factor-Based Progression Risk Stratification and Tumor Grading of Non-Muscle-Invasive Bladder Cancer. Cancers, 14(19), 4570. https://doi.org/10.3390/cancers14194570